Literature DB >> 25212258

Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations.

Elisabetta Patorno1, Amanda R Patrick, Elizabeth M Garry, Sebastian Schneeweiss, Victoria G Gillet, Dorothee B Bartels, Elvira Masso-Gonzalez, John D Seeger.   

Abstract

BACKGROUND: Recent years have witnessed a growing body of observational literature on the association between glucose-lowering treatments and cardiovascular disease. However, many of the studies are based on designs or analyses that inadequately address the methodological challenges involved.
METHODS: We reviewed recent observational literature on the association between glucose-lowering medications and cardiovascular outcomes and assessed the design and analysis methods used, with a focus on their ability to address specific methodological challenges. We describe and illustrate these methodological issues and their impact on observed associations, providing examples from the reviewed literature. We suggest approaches that may be employed to manage these methodological challenges.
RESULTS: From the evaluation of 81 publications of observational investigations assessing the association between glucose-lowering treatments and cardiovascular outcomes, we identified the following methodological challenges: 1) handling of temporality in administrative databases; 2) handling of risks that vary with time and treatment duration; 3) definitions of the exposure risk window; 4) handling of exposures that change over time; and 5) handling of confounding by indication. Most of these methodological challenges may be suitably addressed through application of appropriate methods. CONCLUSIONS/
INTERPRETATION: Observational research plays an increasingly important role in the evaluation of the clinical effects of diabetes treatment. Implementation of appropriate research methods holds the promise of reducing the potential for spurious findings and the risk that the spurious findings will mislead the medical community about risks and benefits of diabetes medications.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25212258     DOI: 10.1007/s00125-014-3364-z

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  121 in total

1.  Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting.

Authors:  Shoko Maru; Gary G Koch; Monika Stender; Douglas Clark; Laura Gibowski; Hans Petri; Alice D White; Ross J Simpson
Journal:  Diabetes Care       Date:  2005-01       Impact factor: 19.112

2.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

3.  Confounding by indication.

Authors:  A M Walker
Journal:  Epidemiology       Date:  1996-07       Impact factor: 4.822

4.  Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.

Authors:  Daniel M Hartung; Daniel R Touchette; Nanette C Bultemeier; Dean G Haxby
Journal:  Pharmacotherapy       Date:  2005-10       Impact factor: 4.705

5.  The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.

Authors:  Catherine B Johannes; Carol E Koro; Sherry G Quinn; Jennifer A Cutone; John D Seeger
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-05       Impact factor: 2.890

6.  Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

Authors:  Jeffrey A Johnson; Sumit R Majumdar; Scot H Simpson; Ellen L Toth
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

7.  Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan.

Authors:  Fei-Yuan Hsiao; Yi-Wen Tsai; Yu-Wen Wen; Pei-Fen Chen; Hao-Yu Chou; Chen-Huan Chen; Ken N Kuo; Weng-Foung Huang
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-08       Impact factor: 2.890

8.  Effect of rosiglitazone on survival in patients with diabetes mellitus treated for coronary artery disease.

Authors:  Alana Choy-Shan; Andrew Zinn; Binita Shah; Ann Danoff; Robert Donnino; Arthur Z Schwartzbard; Jeffrey D Lorin; Eugene Grossi; Steven P Sedlis
Journal:  Coron Artery Dis       Date:  2012-08       Impact factor: 1.439

9.  Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.

Authors:  Christianne L Roumie; Adriana M Hung; Robert A Greevy; Carlos G Grijalva; Xulei Liu; Harvey J Murff; Tom A Elasy; Marie R Griffin
Journal:  Ann Intern Med       Date:  2012-11-06       Impact factor: 25.391

10.  Overadjustment bias and unnecessary adjustment in epidemiologic studies.

Authors:  Enrique F Schisterman; Stephen R Cole; Robert W Platt
Journal:  Epidemiology       Date:  2009-07       Impact factor: 4.822

View more
  20 in total

Review 1.  Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review.

Authors:  Elisabetta Patorno; Elizabeth M Garry; Amanda R Patrick; Sebastian Schneeweiss; Victoria G Gillet; Olesya Zorina; Dorothee B Bartels; John D Seeger
Journal:  Drug Saf       Date:  2015-03       Impact factor: 5.606

2.  Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care.

Authors:  Elisabetta Patorno; Chandrasekar Gopalakrishnan; Kimberly G Brodovicz; Andrea Meyers; Dorothee B Bartels; Jun Liu; Martin Kulldorff; Sebastian Schneeweiss
Journal:  Diabetes Obes Metab       Date:  2019-05-01       Impact factor: 6.577

3.  Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records.

Authors:  Elisabetta Patorno; Chandrasekar Gopalakrishnan; Jessica M Franklin; Kimberly G Brodovicz; Elvira Masso-Gonzalez; Dorothee B Bartels; Jun Liu; Sebastian Schneeweiss
Journal:  Diabetes Obes Metab       Date:  2018-01-12       Impact factor: 6.577

Review 4.  Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes.

Authors:  Elisabetta Patorno; Sebastian Schneeweiss; Shirley V Wang
Journal:  Diabetes Obes Metab       Date:  2020-04       Impact factor: 6.577

5.  Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.

Authors:  Elisabetta Patorno; Ajinkya Pawar; Jessica M Franklin; Mehdi Najafzadeh; Anouk Déruaz-Luyet; Kimberly G Brodovicz; Steven Sambevski; Lily G Bessette; Adrian J Santiago Ortiz; Martin Kulldorff; Sebastian Schneeweiss
Journal:  Circulation       Date:  2019-04-08       Impact factor: 29.690

6.  Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data.

Authors:  Katsiaryna Bykov; Mengdong He; Jessica M Franklin; Elizabeth M Garry; John D Seeger; Elisabetta Patorno
Journal:  Diabetes Obes Metab       Date:  2019-05-29       Impact factor: 6.577

7.  Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes.

Authors:  HoJin Shin; Sebastian Schneeweiss; Robert J Glynn; Elisabetta Patorno
Journal:  Pharmacoepidemiol Drug Saf       Date:  2022-01-17       Impact factor: 2.890

Review 8.  Does Metformin Reduce Cancer Risks? Methodologic Considerations.

Authors:  Asieh Golozar; Shuiqing Liu; Joeseph A Lin; Kimberly Peairs; Hsin-Chieh Yeh
Journal:  Curr Diab Rep       Date:  2016-01       Impact factor: 4.810

9.  Case-control study of oral glucose-lowering drugs in combination with long-acting insulin and the risks of incident myocardial infarction and incident stroke.

Authors:  James S Floyd; Kerri L Wiggins; Mark Christiansen; Sascha Dublin; William T Longstreth; Nicholas L Smith; Barbara McKnight; Susan R Heckbert; Noel S Weiss; Bruce M Psaty
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-11-08       Impact factor: 2.890

10.  Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies.

Authors:  Manel Pladevall; Nuria Riera-Guardia; Andrea V Margulis; Cristina Varas-Lorenzo; Brian Calingaert; Susana Perez-Gutthann
Journal:  BMC Cardiovasc Disord       Date:  2016-01-15       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.